Toggle menu

RATPAC

Start date:
Historic
End date:
June 2009
Co-ordinated by:
University of Sheffield

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – a trial of rapid blood testing for acute chest pain in six NHS hospitals around the UK.

Aim

To evaluate the clinical effectiveness and cost-effectiveness of the most promising point-of-care cardiac marker panel currently used in the emergency department.

Trial Design

Multi centre randomised controlled trial of point of care markers vs standard care in patients with acute chest pain in the Emergency Department.

List of Publications – References

Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011;97:190–6.

Fitzgerald P, Goodacre SW, Cross E, Dixon S: Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel Assay of cardiac markers (RATPAC) trial. Acad Emerg Med 2011; 18(5): 488-95.

Bradburn M, Goodacre SW, Fitzgerald P, Coats T, Gray A, Hassan T, Humphrey J, Kendall J, Smith J, Collinson P; RATPAC Research Team: Interhospital variation in the RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Emerg Med J 2012; 29(3): 233-8.

Goodacre S, Bradburn M, Fitzgerald P Cross E, Collinson P, Gray A and Hall AS. The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technology Assessment. (2011);15(23).

P Collinson, S Goodacre, D Gaze and A Gray. Very Early Diagnosis Of Chest Pain By Point Of Care Testing; Comparison Of The Diagnostic Efficiency Of A Panel Of Cardiac Biomarkers Compared To Troponin Measurement Alone In The Randomised Assessment Of Panel Assay Of Cardiac Markers (RATPAC) Trial. Heart. (2012);98:312-318.

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)